In line with this meta-analysis, our results discovered higher expression of XRCC4 protein in tissues from ovarian carcinoma patients than that from healthy controls, and elevated level of XRCC4 mRNA was significantly linked to worse survival for ovarian malignance patients, particularly in serous, grade III and all stages, implying XRCC4 might be a poor prognostic biomarker in ovarian carcinomas. Here, XRCC4 is linked to ovarian carcinoma.